This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Cefotetan
Description: Cefotan is a cephamycin antibiotic, a group of beta lactams that is commonly grouped with second generation cephalosporins due to their similar properties. Compared to first generation cephalosporins such as Keflex, second generation cephalosporins exhibit better Gram-(-) activity and somewhat weaker Gram-(+) activity. They are more stable to Gram-(-) beta lactamases. They exhibit good activity against many enteric Gram-(-) rods, Haemophilus influenzae, and Neisseria gonorrheae; moderate activity against streptococci and staphylococci; and poor activity against enterococci, methacillin resistant Staphylococcus aureus and Psuedomonas. In addition to these activities, the cefamycins exhibit activity against anaerobes.
AstraZeneca and IGI Laboratories
In September 2014, IGI Laboratories acquired the regulatory rights and related documents and records for 18 drug products from AstraZeneca, 17 of which were marketed. The acquisition includes the regulatory rights and documents for 17 injectable products and 1 suppository product. All of these products had been previously approved by the US FDA as abbreviated new drug applications (ANDAs) or new drug applications (NDAs) prior to their discontinuation or withdrawal from the market.
Pink Sheet AstraZeneca to halt Cefotan sales
Pink Sheet Stuart's Cefotan launch
Pink Sheet Zeneca/Voluntary Hospitals of America
Pink Sheet Patent extension requests
Additional information available to subscribers only: